Printer Friendly

EPIX Pharmaceuticals Announces Formation of Technology Advisory Board.

Board Comprised of Leaders in the Computational Technologies Field

LEXINGTON, Mass. -- EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, today announced the formation of a Technology Advisory Board (TAB) that includes several leaders in the field of computational technologies. The EPIX TAB has been established to advise the company on key aspects of its computational technologies including EPIX's proprietary in silico modeling for drug discovery. The charter members of the TAB, convening its inaugural session this week, include Charles L. Brooks, III, Ph.D., Johan Aqvist, Ph.D., and Gabriele Cruciani, Ph.D.

"We are pleased to announce the formation of the EPIX Technology Advisory Board and welcome the additional experience and knowledge of these accomplished thought-leaders, which should be additive to our current and future in silico discovery and development efforts," said Hanoch Senderowitz, executive director of Computational Development. "We believe the TAB is a vital strategic asset for our continued growth, and we look forward to collaborating with the members of our TAB as we continue to pursue new discovery targets, develop our lead therapeutic product candidates and expand our proprietary technology footprint."

About the EPIX TAB

Charles L. Brooks, III, Ph.D.

Professor Brooks is the Warner-Lambert/Parke-Davis professor of chemistry and a professor of biophysics in the Department of Chemistry at the University of Michigan.

Professor Brooks' research interests focus on the application of statistical mechanics, quantum chemistry and computational methods to chemically- and physically-oriented problems in biology. His current research interests include: free energy based methods for screening and optimization lambda-dynamics; ligand docking, protein stability and continuum based free energy approximations; the development of new polarizable force fields for proteins, lipids and small molecules; protein folding; and, protein structure prediction, ab initio folding, homology modeling. Professor Brooks is the author/co-author of more than 240 journal articles and book chapters.

Johan Aqvist, Ph.D.

Professor Aqvist is a professor of theoretical chemistry in the Department of Cell and Molecular Biology at Uppsala University, Sweden. Research in his group is focused on protein structure and function with a particular emphasis on enzymatic catalysts and binding energies between proteins and their ligands.

Professor Aqvist is the developer of the Linear Interaction Energy (LIE) method which he has successfully applied to the prediction of binding free energies in a variety of systems. Dr. Aqvist also is conducting work on the hERG channel; a large scale hERG binding prediction project is currently ongoing in his lab. Professor Aqvist is the author/co-author of more than 130 journal articles and book chapters.

Gabriele Cruciani, Ph.D.

Professor Cruciani is a professor of organic chemistry and cheminformatics in the Laboratory for Chemometrics and Cheminformatics at the University of Perugia, Italy. In addition, he serves as the scientific director of Molecular Discovery Ltd., a scientific software company focused on the development of computational tools based on the GRID force field with an emphasis on ADMET predictions.

Professor Cruciani's expertise includes ADMET predictions with a particular emphasis on hERG and CYPs. Professor Cruciani is the author/co-author of more than 100 journal articles and book chapters.

About EPIX

EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform. The company has a pipeline of internally-discovered drug candidates currently in clinical development to treat diseases of the central nervous system and lung conditions. EPIX also has collaborations with leading organizations, including GlaxoSmithKline, Amgen, Cystic Fibrosis Foundation Therapeutics and Bayer Schering Pharma. For more information, please visit the company's website at
COPYRIGHT 2008 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Aug 14, 2008
Previous Article:76 percent of U.S. CEOs see greater inbound foreign investment in the next year.
Next Article:NPD Looks at Back-to-School 2008 in Challenging Times.

Related Articles
EPIX Reports Third Quarter 2005 Results; Conference Call Scheduled Today to Include Business Development and Regulatory Update.
Dr. Michael Gilman Joins EPIX Pharmaceuticals Board Of Directors.
EPIX Reports First Quarter 2006 Results; Conference Call Scheduled Today to Include Merger and Regulatory Update.
Michael Astrue Resigns as Interim CEO of EPIX Pharmaceuticals; Consultancy Agreement Put in Place.
EPIX Pharmaceuticals Files Appeal with FDA Regarding Vasovist(TM) Approvable Letters; Company Remains Committed To Making Novel Blood-Pool Imaging...
EPIX Pharmaceuticals Schedules Annual Meeting and Shareholder Vote on Merger with Predix Pharmaceuticals for August 15, 2006.
FDA Extends Review of EPIX Pharmaceuticals' Appeal of Vasovist(TM) Approvable Letters.
EPIX Reports Second Quarter 2006 Results.
EPIX Pharmaceuticals Expands Scientific Advisory Board.
EPIX Pharmaceuticals Files Formal Appeal for Vasovist(TM) with the Center for Drug Evaluation and Research.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters